twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2010
vol. 112
 
Share:
Share:
abstract:
Review article

Intravitreal ranibizumab in diabetic macular edema

Agnieszka Kubicka-Trząska
1

  1. Z Katedry Okulistyki Kliniki Okulistyki i Onkologii Okulistycznej Uniwersytetu Jagiellońskiego Collegium Medicum w Krakowie
Online publish date: 2010/12/22
View full text Get citation
 
Anti-vascular endothelial growth factor (anti-VEGF) therapies that inhibit choroidal angiogenesis and reduce vascular permeability have revolutionized clinical practices for neovascular eye diseases. Ranibizumab (Lucentis) is a Fab-antibody with high affinity for VEGF, and has a potential to bind to all VEGF isoforms. Diseases of retinal and choroidal vasculature are the most prevalent causes of vision loss in developed countries. Among them diabetic macular edema (DME) is the most common sight threatening complication of diabetes. VEGF plays a critical role in the pathogenesis of DME. Due to modest outcomes with macular

photocoagulation, other treatment modalities for DME have been evaluated. The results of the pilot studies and preliminary results of multicenter randomized, controlled studies showed that intraocular injections of ranibizumab decrease the mean retinal thickness and improve the BCVA (best corrected visual acuity) in patients with DME.
keywords:

ranibizumab, diabetic macular edema

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.